Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 190 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Co-Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975
View directory record Official record
Conditions
Hookworm Infections
Interventions
Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
Biological · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

NCT01064947
View directory record Official record
Conditions
Atopic Dermatitis, Secondary Infection
Interventions
Retapamulin 1%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
2 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

NCT05879107
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, PCV20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
1,113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 29, 2026, 8:42 PM EDT
Completed No phase listed Observational

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

NCT00747539
View directory record Official record
Conditions
HIV, Hepatitis C, Infections
Interventions
Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Lancaster, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

NCT00742326
View directory record Official record
Conditions
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

NCT00879047
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Alcohol, Alcohol placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 29, 2026, 8:42 PM EDT
Completed No phase listed Observational

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

NCT01296529
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

NCT02124044
View directory record Official record
Conditions
HIV-HCV
Interventions
Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

NCT05064800
View directory record Official record
Conditions
Healthy Participants
Interventions
Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated Not applicable Interventional Results available

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV, Drug-Induced Liver Injury
Interventions
Shear Wave sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

NCT03187834
View directory record Official record
Conditions
Child Development
Interventions
Azithromycin, Amoxicillin, Cotrimoxazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 59 Months
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PegIFN/RBV, BI201335, BI201335 24W, Bi 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

NCT00423046
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
40
States / cities
Chandler, Arizona • San Diego, California • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Not applicable Interventional Results available

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

NCT03214679
View directory record Official record
Conditions
Hepatitis C, People Who Inject Drugs, PWID, HCV Coinfection
Interventions
Accessible Care, Usual Care
Other
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 29, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons

NCT02316184
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
Motivational Interviewing, Brief Advice
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 29, 2026, 8:42 PM EDT
Completed No phase listed Observational

The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System

NCT01206933
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 29, 2026, 8:42 PM EDT
Terminated No phase listed Observational

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

NCT00340548
View directory record Official record
Conditions
Hemophilia, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 29, 2026, 8:42 PM EDT